Reykjavik, Iceland, 10 May 2007 ― Actavis Group (OMX: ACT) confirms that it has
received an announcement from Novator, an investment firm led by the Chairman
of Actavis, Bjorgolfur Thor Bjorgolfsson. Parties related to Novator, currently
hold approximately 38.5% of total A class shares. Novator's intention is to
acquire the entire class A common shares of the Company.
A new Company within the Novator Group intents to make a voluntary bid to all A
class shareholders of Actavis in Euros. The offer price will be EUR 0.98 per
share, which at the Icelandic Central Bank Fixing Exchange Rate for the Euro on
9 May, equals ISK 85.23 per share.
The Board of directors will review the offer as soon as feasible and make its
recommendation to shareholders.
For further information:
Actavis Group
Halldor Kristmannsson, VP Corporate Communications
(+354) 535-2300 / 840-3425
hkristmannsson@actavis.com
About Actavis Group
Actavis is one of the world's leading generic pharmaceutical companies
specializing in the development, manufacture and sale of generic
pharmaceuticals. Based in Iceland, the company has operations in more than 30
countries, with over 11,000 employees. The Company's market cap is
approximately EUR3.0bn (US$3.8 billion) and it's listed on the OMX Exhange in
Iceland. For further information, visit www.actavis.com